The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia.
The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, Australia.
Am J Ophthalmol. 2018 Jun;190:50-57. doi: 10.1016/j.ajo.2018.03.012. Epub 2018 Mar 14.
To evaluate outcomes and predictive factors of visual acuity (VA) change after cataract surgery in patients being treated for neovascular age-related macular degeneration (nAMD).
Retrospective, matched case-control study.
We studied eyes undergoing cataract surgery that had been tracked since they first started treatment for nAMD. These eyes were compared with a cohort of unoperated phakic eyes being treated for nAMD (3 per case) matched for treatment duration before cataract surgery, baseline VA, age, and length of follow-up.
We included 124 patients that had cataract surgery and 372 matched controls. The mean (95% confidence interval) VA gained was 10.6 letters (7.8, 13.2; P < .001) 12 months after surgery; 26.0% had gained ≥3 lines and 1.6% had lost ≥3 lines of VA. Visual acuity (mean [standard deviation]) 12 months after surgery was higher in eyes that had cataract extraction compared with controls (65.8 [17.1] vs 61.3 [20.8] letters, respectively, P = .018). The proportion of visits where the choroidal neovascular (CNV) lesion was graded active and the mean number of injections were similar before and after surgery (P = .506 and P = .316, respectively), whereas both decreased in the control group, suggesting that surgery modestly increased the level of activity of the CNV lesion. Mean [SD] VA prior to surgery was lower in eyes that gained ≥15 letters compared with eyes that gained 0-14 letters (40.2 [21.4] vs 62.1 [15.1], P < .001). Patients undergoing cataract surgery within the first 6 months of anti-VEGF therapy were more likely to lose rather than gain vision (20.8% lost vision vs 12.8% and 4.4% gaining ≥15 or 0-14 letters respectively, P = .023). Age, receiving an injection at least 2 weeks before surgery, and the CNV lesion type had no discernible association with VA outcomes.
We found evidence of a modest effect of cataract surgery on CNV lesion activity in eyes being treated for nAMD. Despite this, visual outcomes were reassuringly good. Cataract surgery within 6 months of starting treatment for nAMD should be avoided if possible.
评估接受新生血管性年龄相关性黄斑变性(nAMD)治疗的患者白内障手术后视力(VA)变化的结果和预测因素。
回顾性、配对病例对照研究。
我们研究了自首次接受 nAMD 治疗以来一直接受跟踪的接受白内障手术的眼睛,并将其与接受 nAMD 治疗的未手术的非白内障眼队列(每例 3 只眼)进行了比较,这些眼在白内障手术前的治疗持续时间、基线 VA、年龄和随访时间方面相匹配。
我们纳入了 124 例接受白内障手术的患者和 372 例匹配的对照者。手术后 12 个月时,VA 平均(95%置信区间)增加了 10.6 个字母(7.8,13.2;P<.001);26.0%的患者视力提高了≥3 行,1.6%的患者视力下降了≥3 行。与对照组相比,接受白内障摘除术的眼睛手术后 12 个月时的 VA 更高(分别为 65.8 [17.1]和 61.3 [20.8]个字母,P=.018)。手术前后脉络膜新生血管(CNV)病变的活跃评分比例和注射的平均次数相似(分别为 P=.506 和 P=.316),而对照组的这两个比例均下降,表明手术适度增加了 CNV 病变的活动程度。与视力提高 0-14 个字母的眼睛相比,视力提高≥15 个字母的眼睛手术前的平均(SD)VA 更低(分别为 40.2 [21.4]和 62.1 [15.1],P<.001)。在抗 VEGF 治疗的头 6 个月内接受白内障手术的患者更有可能视力下降而非提高(20.8%视力下降与 12.8%和 4.4%分别提高≥15 或 0-14 个字母相比,P=.023)。年龄、手术前至少 2 周注射以及 CNV 病变类型与 VA 结果无明显关联。
我们发现白内障手术对接受 nAMD 治疗的患者 CNV 病变活动有适度影响的证据。尽管如此,视力结果还是令人安心的。如果可能,应避免在 nAMD 治疗开始后 6 个月内进行白内障手术。